Delta APACHE II for predicting course and outcome of nosocomial Staphylococcus aureus bacteremia and its relation to host defense

The Journal of Infectious Diseases
E P YzermanH A Verbrugh

Abstract

To predict at an early phase the clinical course and outcome of nosocomial Staphylococcus aureus bacteremia, the APACHE II score at onset of bacteremia was calculated in 99 patients. A delta APACHE II score (i.e., the difference between this score and one calculated for the day before the bacteremia) was also determined. This delta APACHE II score was highly significantly correlated with clinical course (P<.001) and outcome (P<.001). The risk of a complicated clinical course and of dying from S. aureus bacteremia is determined at the very onset of bacteremia, and this risk can best be assessed by calculating the delta APACHE II score. Furthermore, a positive correlation was found between delta APACHE II scores and the level of serum opsonic activity (P=.003) toward S. aureus. Therefore, the complicated clinical course of S. aureus bacteremia is not due to a relative lack of specific opsonins.

Citations

Nov 5, 2004·Annals of Hematology·Mohamed Mabed, Samy Marouf
Aug 26, 1998·The New England Journal of Medicine·F D Lowy
Nov 14, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J M Mylotte, A Tayara
Apr 1, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Maite Garrouste-OrgeasUNKNOWN OUTCOMEREA Study Group
Dec 23, 2011·The Pediatric Infectious Disease Journal·Eyal LeshemGili Regev-Yochay
Apr 12, 2012·Clinical Microbiology Reviews·Sebastian J van HalIain B Gosbell
Dec 13, 2006·American Journal of Infection Control·Alan J Lesse, Joseph M Mylotte
Jul 8, 1999·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·L SoufirS Chevret
Dec 2, 2004·The Journal of Hospital Infection·M PirsonP Leclercq
Dec 13, 2005·Scandinavian Journal of Infectious Diseases·Riad KhatibSajjad Saeed
Dec 3, 2014·Immunology Letters·Martijn A Nolte, Jos W M van der Meer
May 17, 2005·Internal Medicine Journal·M G Thomas, A J Morris
Jun 8, 2000·Journal of Acquired Immune Deficiency Syndromes : JAIDS·C OmeñacaJ Cadden
Oct 10, 2008·The Cochrane Database of Systematic Reviews·Miranda van RijenJan Kluytmans
Sep 30, 2003·Scandinavian Journal of Infectious Diseases·Dominique W M VerhagenPeter Speelman
Jan 16, 2004·Scandinavian Journal of Infectious Diseases·Leonard B JohnsonRiad Khatib

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.